Sodium acetrizoate
| File:Sodium acetrizoate.svg | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C9H5I3NNaO3 |
| Molar mass | 578.844 g/mol |
Sodium acetrizoate (rINN, trade names Urokon, Triurol and Salpix), the sodium salt of acetrizoic acid, is a high-osmolality, water-soluble, iodine-based radiographic contrast medium no longer in clinical use.[1]
Acetrizoate was developed by V.H. Wallingford of Mallinckrodt, and introduced in 1950;[2] it was employed as a contrast agent for several radiographic studies, including pyelography,[3][4] angiography of the brain, carotid arteries and the aorta,[5][6] and cholecystography.[7][8] It was soon found to be highly toxic to the kidneys and nervous system—work urging caution in its administration was published as early as 1959,[9] after reports of adverse reactions ranging from hypersensitivity to brain damage—and was eventually replaced by other agents with higher efficacy and lower toxicity, such as sodium diatrizoate, a closely related compound.[2]
References
- ↑ "Acetrizoate sodium". Online Medical Dictionary. University of Newcastle upon Tyne. March 5 2000. Retrieved 2007-11-14. Check date values in:
|date=(help) - ↑ 2.0 2.1 McClennan BL (1990). "Preston M. Hickey memorial lecture. Ionic and nonionic iodinated contrast media: evolution and strategies for use". AJR. American journal of roentgenology. 155 (2): 225–33. PMID 2115244.
- ↑ NESBIT RM, LAPIDES J (1950). "Preliminary report on urokon, a new excretory pyelographic medium". J Urol. 63 (6): 1109–12. PMID 15422724.
- ↑ EYLER WR, DREW DR, BOHNE AW (1956). "A comparative clinical trial of urographic media: renografin, hypaque, and urokon". Radiology. 66 (6): 871–3. PMID 13323329.
- ↑ LIU P, MURTAGH F, WYCIS HT, SCOTT M (1953). "Report of one hundred carotid angiograms taken with the new contrast medium acetrizoate (urokon) on Chamberlain's biplane stereoscopic angiographic unit". A. M. A. archives of neurology and psychiatry. 69 (5): 651–2. PMID 13039633.
- ↑ SEAMAN WB, SCHWARTZ HG (1953). "Cerebral arteriography with sodium acetrizoate (urokon sodium) 30%". A.M.A. archives of surgery. 67 (5): 741–5. PMID 13103941.
- ↑ ORLOFF TL (1955). "Intravenous cholecystography with a new medium; experience with sodium acetrizoate (urokon sodium) seventy per cent". A.M.A. archives of surgery. 71 (4): 620–2. PMID 13258064.
- ↑ WOOLLEY IM, KEIZUR LW, MAYERHARNISCH G (1957). "Gallbladder visualization following the use of 70 per cent sodium acetrizoate (urokon sodium) for intravenous pyelography". Radiology. 69 (4): 576–7. PMID 13485425.
- ↑ LANCE EM, KILLEN DA, SCOTT HW (1959). "A plea for caution in the use of sodium acetrizoate (urokon) for aortography". Ann Surg. 150 (1): 172. PMID 13661846. PMC 1613496
- Pages with script errors
- CS1 errors: dates
- CS1 maint: Multiple names: authors list
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Organoiodides
- Radiocontrast agents